Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference
30 août 2021 16h05 HE | Olema Oncology
SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update
10 août 2021 16h05 HE | Olema Oncology
Presentation of preliminary Phase 1/2 dose-escalation data for OP-1250 in patients with metastatic, ER+ / HER2- breast cancer planned for Q4 2021Strong cash, cash equivalents and marketable securities...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference
28 juil. 2021 16h05 HE | Olema Oncology
SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference
18 mai 2021 16h05 HE | Olema Oncology
SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update
11 mai 2021 16h05 HE | Olema Oncology
OP-1250 continues to advance in dose-escalation stage of Phase 1/2 clinical trial in patients with metastatic, ER+ / HER2- breast cancer; Initial data anticipated in 2H 2021Cash, cash equivalents, and...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
07 avr. 2021 07h30 HE | Olema Oncology
SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors
06 avr. 2021 07h30 HE | Olema Oncology
Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its PipelineLongstanding Olema Director Dr. Frank...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
17 mars 2021 16h05 HE | Olema Oncology
Advancing OP-1250 in metastatic, ER+ / HER2- breast cancer Phase 1/2 clinical trialClinical trial agreements announced with Novartis and Pfizer to explore combination of OP-1250 with CDK4/6 inhibitors...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
10 mars 2021 16h45 HE | Olema Oncology
SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology to Participate at Upcoming Virtual Investor Conferences
23 févr. 2021 07h00 HE | Olema Oncology
SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...